PCOS Symptoms (Now PMOS): What to Check and Why the Driver Matters

The PMOS symptoms people notice first are rarely the ones that explain what is driving the condition. This page covers which PMOS symptoms matter, how the diagnosis is made, and why the dominant driver decides what happens next.

PMOS is the new name for PCOS

PMOS, or Polyendocrine Metabolic Ovarian Syndrome, is the new name for the condition previously known as PCOS. The name was changed in May 2026 through a global consensus process involving more than fifty patient and professional organisations, because the condition is much more than “polycystic ovaries”. It is an endocrine and metabolic condition that can affect ovulation, hormones, insulin sensitivity, body composition, skin, fertility and long-term metabolic health.
There is a three-year transition period, and the new name will be fully reflected in the 2028 international guideline update. You will therefore still see PCOS used widely, including by other clinics and in older test reports. The diagnostic criteria have not changed.
At iLIV, we believe getting the diagnosis is only the first step. Two women can both meet the diagnostic criteria for PMOS and still have very different hormonal and metabolic patterns, and therefore may need very different management.

How PMOS is diagnosed

In adults, diagnosis generally requires at least two of the following three features, after other possible causes have been excluded.

1. Ovulatory dysfunction

This may present as irregular, very long or absent menstrual cycles.

2. Clinical or biochemical hyperandrogenism

This can appear as acne, excess facial or body hair, scalp hair thinning, or elevated androgen levels on blood testing.

3. Polycystic ovarian morphology

This may be assessed using ultrasound or, in appropriate adults, Anti-Mullerian Hormone according to current international guidance.
Having polycystic-looking ovaries alone does not automatically mean you have PMOS. Equally, someone can have PMOS without a classic polycystic appearance on ultrasound.

PMOS is not simply a weight problem

Insulin resistance is an important biological feature in many people with PMOS. When insulin levels and insulin signalling are disrupted, this can influence ovarian androgen production and contribute to irregular ovulation, acne and excess hair growth.
But not every patient with PMOS carries excess weight. Lean women can also have PMOS, metabolic dysfunction or androgen excess. This is one reason treatment should not be reduced to “lose weight”.

Which PMOS symptoms should be checked

Testing should be guided by the individual rather than ordering the same large panel for everyone. Depending on symptoms and history, assessment may include testosterone and other androgens, SHBG, DHEA-S, LH and FSH, prolactin, thyroid function, glucose regulation and HbA1c, lipid profile, metabolic health and body composition, vitamin and nutritional status where relevant, and ultrasound or AMH when indicated.
Other investigations may be needed when symptoms suggest another endocrine or adrenal condition.

At iLIV, diagnosis is only the starting point

PMOS is a heterogeneous condition. Two people can receive the same diagnosis while having very different combinations of insulin resistance, androgen excess, ovulatory dysfunction, inflammation, adrenal androgen activity, body-composition concerns, nutritional deficiencies, sleep and stress problems, and fertility goals.
Because of this, we do not stop once the diagnosis is made. After confirming it and excluding important alternative causes, we assess the phenotype, the metabolic health and the possible dominant drivers. As part of our functional and integrative approach, we commonly look at four clinical patterns.

Insulin-resistant or metabolic-dominant PMOS

One of the most common patterns we see. Features may include central weight gain, difficulty losing weight, prediabetes or abnormal glucose regulation, metabolic syndrome, a strong family history of diabetes, increased appetite or cravings, fatty liver, and androgen symptoms occurring alongside metabolic dysfunction. For these patients, improving metabolic health and insulin sensitivity may become an important part of the strategy.

Post-pill or post-hormonal-contraception pattern

Some women first notice irregular cycles, acne or androgen symptoms after stopping hormonal contraception. This does not mean the pill caused PMOS. Hormonal contraception can suppress ovulation and androgen-related symptoms, so stopping it can reveal an underlying tendency that was previously masked. We assess whether there is true underlying PMOS, a temporary post-pill disturbance, or another cause of irregular ovulation before deciding on treatment.

Adrenal-dominant pattern

Not all androgen excess comes predominantly from the ovaries. In some patients, adrenal androgens such as DHEA-S are more prominent, so stress physiology, sleep, recovery and other endocrine factors may need closer assessment. Significant adrenal androgen elevation also requires doctors to consider and exclude other adrenal conditions rather than attributing everything to PMOS.

Inflammatory pattern

PMOS is associated with metabolic and inflammatory abnormalities, and some patients appear to carry a greater inflammatory burden alongside their hormonal symptoms. Here we may look more closely at metabolic health, visceral adiposity, sleep, nutrition, gut symptoms, lifestyle, and chronic inflammatory conditions where clinically relevant. The aim is not to suppress symptoms but to identify modifiable factors contributing to the overall picture.

These are patterns, not four separate diseases

The four patterns above are not official diagnostic categories of PMOS. They are a clinical framework we use to understand what may be contributing most strongly to an individual presentation. Many patients do not fit neatly into one box. Someone may have significant insulin resistance together with inflammatory factors and raised adrenal androgens. That is why we focus on the individual phenotype and dominant drivers rather than assigning everyone the same protocol.

Why identifying the dominant driver matters

Because management may differ. One patient may need to prioritise insulin sensitivity and metabolic treatment. Another may need more attention to androgen excess and cycle regulation. For another, fertility is the immediate goal. Another may need nutritional deficiencies, sleep problems, stress physiology or inflammatory contributors treated alongside conventional PMOS management.
A personalised PMOS plan at iLIV may therefore combine nutrition, exercise and resistance training, body-composition management where appropriate, work on insulin sensitivity and metabolic health, menstrual-cycle and hormone management, fertility optimisation, sleep and stress management, correction of relevant nutritional deficiencies, evidence-based medication where indicated, and selected nutraceutical support where appropriate. The plan is built around the person, not the diagnosis alone.

When symptoms that look like PMOS are not PMOS

Several conditions can produce a similar picture, including thyroid dysfunction, high prolactin, hypothalamic amenorrhoea from under-fuelling or excessive exercise, certain adrenal disorders, and other causes of androgen excess.
Rapidly worsening facial hair, sudden severe acne, significant androgen elevation or voice deepening deserve further assessment rather than being assumed to be PMOS. This is why proper evaluation comes before treatment.

The iLIV approach to PMOS

We look beyond the label. Diagnosis, then phenotype, then dominant drivers, then personalised management. Rather than giving every patient the same protocol, we assess the hormonal, metabolic and lifestyle picture and build treatment around what she actually needs.
If you have irregular periods, androgen symptoms, difficulty losing weight, metabolic concerns or fertility issues, a proper assessment can help determine whether PMOS is present and, importantly, what may be driving your particular presentation.

What gets checked and why is set out in the hormone profile test and the metabolic assessment. If insulin resistance is the dominant driver, read GLP-1 for PCOS and insulin resistance. The full hormone and midlife pathway is at hormones and midlife, and the hormone treatment option at hormone therapy. Book a consultation for an assessment. The WHO fact sheet gives a short overview of the condition.

Every iLIV guide is written and reviewed under our editorial standards, and each one carries the name of the reviewing doctor together with their MMC registration number.

Frequently Asked